CHERRY HILL, N.J., July 8 Nuvilex, Inc. (OTC Bulletin Board: NVLX), today announced that it will host an investor conference call on Tuesday, July 14, 2009 at 4:30 PM Eastern Time to discuss current trends in the business and provide an update on the Company's launch of the Last Shot Hangover Remedy.
"In a very difficult economy and market, we are making extraordinary progress towards achieving our stated goals for the current fiscal year," said Martin Schmieg, Chairman and CEO of Nuvilex, Inc. "Based on the recent decline in our stock price, we do not think our current market cap appropriately reflects the remarkable advancements we have been making. As such, we are refining our investor relations program to ensure that our message is being told, heard and understood by both new and existing shareholders. We hope that Tuesday's call will be the start of a change in investor sentiment commensurate with the notable work that is being done to grow the Company's revenues and profits."
To participate in the call, please dial 1-877-407-4018 (U.S.) and 1-201-689-8471 (international). A replay of the call will be available from 7:30 PM ET on July 14, through 11:59 PM ET on July 21. To access the replay, please dial 1-877-660-6853 (U.S.) and 1-201-612-7415 (international). Participants should use account number 3055 and conference ID number 327957 to access the replay.
The call will also be webcast. To access the webcast, please go to: http://viavid.net/dce.aspx?sid=00006703 . A replay of the webcast will also be available at www.nuvilex.com.
About Nuvilex, Inc.
Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen, which promotes a healthy glucose metabolism; Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink (R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink (R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.
Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Investor Relations Contacts: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: firstname.lastname@example.org Amy Glynn/Ashleigh Barreto The Ruth Group Ph: 646-536-7023/7028 Email: email@example.com Email: firstname.lastname@example.org Press Contact: Pat Arcand Arcand & Madison Ph: 617-576-7777 Email: email@example.com
SOURCE Nuvilex, Inc.